Workflow
Logic
icon
Search documents
生态种养、科技助力 “新农人”玩转智慧农业 在希望田野上奏响致富“乐章”
Yang Shi Wang· 2025-05-11 07:42
根据物联网虫情监测系统提供的信息,植保无人机在麦田上精准喷洒混合液。 据气象部门统计,2025年以来,丰县累计降雨量60.9毫米,为近10年同期平均水平的4成。近期,当地农业、水务等部门根据自动气象站反馈 的天气和土壤墒情信息,对灌溉水源进行科学调配,确保小麦能够及时浇足灌浆水。目前,丰县65万亩小麦已基本完成两轮精准灌溉,后续灌 溉将视天气情况做出调整。 农田建气象观测站 数字化服务助增收 在山东济宁市兖州区,39万亩小麦同样进入了灌浆关键期。田垄间设置的各类气象观测设备,以分钟级精度捕捉温湿度、风速、土壤墒情等数 据,为小麦增产提供科技保障。 在济宁市兖州区漕河镇的麦田里,植保无人机正开展喷施作业。 央视网消息:近期,江苏徐州市丰县65万亩小麦进入灌浆期。当地通过物联网虫情监测、无人机植保、科学调水等一系列措施,为夏粮丰产丰 收提供保障。 随着气温逐渐升高,农业病虫害也有抬头的趋势。在徐州市丰县,2025年,农业部门新升级了物联网虫情监测系统,24小时不间断采集害虫种 类、数量及活动轨迹等数据,结合环境参数形成多维监测体系,及时掌握病虫害发生情况。 预警信息是山东省气象服务中心通过App发送的。同时,农户 ...
北京用科博会递交科技创新答卷
Bei Jing Qing Nian Bao· 2025-05-10 01:55
以"科技引领创享未来"为主题,昨日,第二十七届中国北京国际科技产业博览会(简称北京科博会)正式开展。作为中国首个以科技为主题的国际性展 会,这场占地5万平方米、汇聚800余家参展机构的科技盛会,不仅是前沿技术的竞技场,更是北京科创生态的集中呈现——从实验室突破到产业化落地,从 人才培育到资本赋能,北京正以系统性政策矩阵推动科创要素高效流动,构建起具有全球竞争力的创新生态。 机器狗吸引小朋友近距离观察 摄影/北京青年报记者 杨益 窥见未来生活样貌 打卡一场科技味儿十足的展览盛宴,当然要从机器人开始。自从机器人半马开始,获得亚军的N2机器人凭借稳定的步态、小小的身姿在网上火了一 把。在北京上学的小付当时就被种了草。"机器人也有这等萌物,真想摸一把。"知道它会出现在本届科博会上,她马上就约了科博会首日的门票,见识了本 届科博会上多位"明星"——北京机器人马拉松冠、亚军"选手"天工2.0和N2以及"入职"全球最多工厂的Walker S1等人形机器人。 其中,"天工2.0"人形机器人以173厘米身高、73公斤体重的工业级体型,展示了复杂地形自适应行走、双电池快速换电等国际领先技术。其背后的"慧 思开物"通用具身智能平台 ...
Senti Biosciences (SNTI) 2025 Conference Transcript
2025-05-08 18:00
Senti Biosciences (SNTI) 2025 Conference May 08, 2025 01:00 PM ET Speaker0 Are you ready to kick it off? Yeah. Whenever you guys wanna do. Speaker1 Okay. Welcome back to the Citizens Life Science Conference. My name is Silvan Turca, and I'm a senior analyst covering precision medicines. And now it's my pleasure to introduce Sandi Biosciences. Presenting will be Tim Liu, CEO and cofounder, and Jay Cross, CFO. Thank you so much for coming and joining us today. Speaker0 Well, thanks a lot, Silvan. Appreciate t ...
AxoGen(AXGN) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:02
AxoGen (AXGN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Michael Dale - President, CEO & Board DirectorNir Naor - Chief Financial OfficerJens Schroeder Kemp - Chief Marketing OfficerCaitlin Cronin - DirectorChris Pasquale - Partner - Medical Devices & SuppliesBrett Gasaway - VP - Equity ResearchMatthew Park - Equity Research AssociateRick Ditto - VP, Global Health Economics, Reimbursement & PolicyJayson Bedford - Managing Director - Medical Technology Conference Call Participants Mi ...
AxoGen(AXGN) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:00
AxoGen (AXGN) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director Nir Naor, Chief Financial Officer and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter twenty twenty five financial results and corporate highlights. Nir will then provide an analysis of our financial performance and guidance and discuss our outlook for the year, followed by a question and answer session. ...
MKS Breaks Ground on New Chemical Manufacturing and TechCenter Facility in Thailand
Globenewswire· 2025-05-07 13:00
ANDOVER, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- MKS Instruments. Inc. (NASDAQ: MKSI) ("MKS"), a global provider of enabling technologies that transform our world, announced today the groundbreaking of its cutting-edge Atotech chemical manufacturing and TechCenter facility at the Asia Industrial Estate Suvarnabhumi, located east of Bangkok, Thailand. This strategic investment aligns with MKS' commitment to grow alongside its customers and deliver localized expertise to accelerate technological advancements ...
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
Globenewswire· 2025-05-07 12:00
Recent Highlights and Anticipated Milestones: Bitopertin: GlyT1 Inhibitor (Heme Synthesis Modulator) DISC-0974: Anti-Hemojuvelin Antibody (Hepcidin Suppression) Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including init ...
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
Globenewswire· 2025-05-06 20:35
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 do ...
BioAtla(BCAB) - 2025 Q1 - Earnings Call Transcript
2025-05-06 20:30
Bioatla (BCAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to today's BioAtlas First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. I will be standing by should you need any assistance. And it is now my pleasure to turn the conference over to Bruce Mackle with LifeSci Advisors. Please go ahead. Speaker1 Thank you, opera ...
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
Globenewswire· 2025-05-06 20:05
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab ...